# Junta clínica — PT-pseudo_b9aa0df93f2a (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b9aa0df93f2a",
  "pid": "PT-pseudo_b9aa0df93f2a",
  "task": 1,
  "psa": 5.5,
  "age": 71,
  "months": 1,
  "pirads": "5",
  "psad": 0.12,
  "psav": 1.47,
  "psap": 3.8,
  "vol": 49.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8111057,
  "medhx": "Hypertension",
  "meds": "amlodipine, lisinopril, metoprolol",
  "notes": "PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.",
  "pmhx": [
    "Hypertension"
  ],
  "allergies": [],
  "vitals": {
    "weight": "116 kg",
    "height": "175 cm",
    "bmi": "37.9",
    "bp": "149/83 mmHg",
    "hr": "65 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "04 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result."
    },
    {
      "s": "History",
      "t": "A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test"
  ],
  "alcohol": "2 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9aa0df93f2a
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 5.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8111057 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.

Vitals: weight 116 kg, height 175 cm, BMI 37.9, BP 149/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result.

History: A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent.

Physical examination: Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent.

Patient info: warehouse manager; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.16 epistemic (95% band 0.25-0.86); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.12: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."
  2. distance 1.26: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  3. distance 1.61: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines discuss the use of MRI-based indications for biopsy, particularly concerning the PI-RADS score and PSA density. "A PI-RADS threshold of $\\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline makes the decision dependent on the PI-RADS score and PSA density, which are already known.
EXPERT-LIBRARY, the precedents suggest a biopsy in several cases, but the guideline makes the decision based on specific risk factors that may differ from this patient's profile.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the rate of PSA change: the rate of PSA change is a factor that the guideline makes decisive in determining the need for further investigation.
laboratory_results - the PSA density: the PSA density is a factor that the guideline makes decisive in determining the need for further investigation.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade of the prior biopsy and the rate of PSA change, as the guideline suggests these factors are decisive.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
  psa_trend (get_psa_trend) -> What is the rate of PSA change?
  previous_notes (get_previous_notes) -> What is the grade of the prior biopsy, and is there a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> What is the PSA density?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason/ISUP) of the prior biopsy?
  Q2. What is the rate of PSA change?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size 12 mm and located in the left peripheral zone at the mid-gland level.

psa_trend
What is the rate of PSA change?
PSA 1.5 (Aug 2023) rising to 1.2 (May 2024), then to 5.5 (Feb 2025).

previous_notes
What is the grade of the prior biopsy, and is there a surveillance protocol with a confirmatory biopsy due?
The grade of the prior biopsy is not recorded, and there is no surveillance protocol with a confirmatory biopsy due.

laboratory_results
What is the PSA density?
The PSA density is 0.12 ng/mL/mL.

WHAT I DID NOT OPEN
family-history anamnesis, because the decision hinges on the documented prior biopsy status and PSA trend.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the left mid peripheral zone supports biopsy due to high imaging risk.
PSA rising from 1.5 to 5.5 ng/mL over the period supports biopsy due to rising PSA rate.

AGAINST sampling this patient now
The grade of the prior biopsy is not recorded, which prevents a definitive assessment of the need for further tissue.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 5.50 ng/mL over 3 points spanning 18 months; velocity +2.67 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 6.5 ng/mL, conformal 95% band 1.9-22.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.68
  uncertainty  +/- 0.16 epistemic (95% band 0.36-1.00), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.68  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.65 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have answered the moderator's questions regarding the prior biopsy grade and the rate of PSA change.

ALIGNMENT WITH THE PANEL
The retrieved findings, specifically the rising PSA trend and the lack of a recorded prior biopsy grade in the previous notes, align with the PANEL-PROTOCOL's decision to recommend biopsy, as the protocol states that when the documented prior grade is not recorded, the trained experts decide.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason/ISUP) of the prior biopsy? Answered by the registrar: "The grade of the prior biopsy is not recorded."
Q2. What is the rate of PSA change? Answered by the registrar: "PSA 1.5 (Aug 2023) rising to 1.2 (May 2024), then to 5.5 (Feb 2025)."

WHAT CARRIES WEIGHT, AND WHY
The rate of PSA change is highly relevant as the EAU guideline explicitly states this is a decisive factor. The lack of a recorded prior biopsy grade is also critical because the panel protocol indicates that this missing piece of information allows the trained experts to make the decision.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the evidence retrieved supports this direction, particularly the rising PSA rate and the absence of a recorded prior biopsy grade.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

71y male, PSA 5.5, PI-RADS 5, prior biopsy grade not recorded. New lesion finding mandates sampling to determine management. Low PSA density argues for observation, but the unrecorded prior grade dictates sampling for definitive risk stratification.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
